17,261 trials
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Heart Failure
Primary: Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) (%) at Week 20 Measured by Echocardiography — -2.19; 2.59; -3.01; 0.13 Percentage of LVEF…
Breast Neoplasms · Bone and Bones
Primary: Bone Resorption (Exercise) — 13.8; 14.7 nm BCE — p=0.86
Moderate Aplastic Anemia · Unilineage Bone Marrow Failure Disorders
Primary: Proportion of Drug Responders — 17 Participants
Pain
Primary: Count/Percentage of Patients Who Report Having Experienced the Paclitaxel-induced Pain Syndrome (PIAPS) for One Week After Paclitaxel After Enrollment to the Current…
Parkinson's Disease Dementia (PDD)
Primary: The Primary Efficacy Objective of This Study is to Assess the Efficacy of SYN120 on Cognition as Determined by the Cognitive Drug Research Computerized Cognition Battery…
Esophageal Cancer · Gastric Cancer
Primary: Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate — 54 Participants
Ulcerative Colitis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to…
Non-metastatic, Hormone naïve Prostate Cancer
Primary: Change in VO2peak in Usual Care Versus Exercise Training Arms — -3.23; -0.92 mL/kg/min
HIV Infections
Primary: Percentage of Participants on the Ruxolitinib Arm Who Experienced Any Safety Milestone Events While On-Treatment — 2.5 percentage of participants
PrEP Adherence Monitoring
Primary: Steady State Concentrations of TFV-DP for Different Dosing Patterns of Truvada — 530; 997; 1605 fmol/punch
Psoriasis
Primary: Number of Participants With On-treatment Serious Adverse Events (SAEs) and Non-SAEs: Part A — 1; 0 Participants
Myeloablative Conditioning · HLA-mismatched Bone Marrow Transplantation · Graft Survival
Primary: Cumulative Incidence of Non-relapse Mortality — 0 percent
Acute Promyelocytic Leukemia
Primary: Complete Response (CR) Rate — 55; 5; 15 Participants
Alopecia Areata
Primary: Total Number of Participants With At Least 50% Hair Regrowth — 1 Participants